Abeona Therapeutics
ABEO
79 hedge funds and large institutions have $64.6M invested in Abeona Therapeutics in 2019 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 23 reducing their positions, and 28 closing their positions.
265% more call options, than puts
Call options by funds: $802K | Put options by funds: $220K
17% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 23
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.04% less ownership
Funds ownership: 2.36% → 2.32% (-0.04%)
19% less funds holding
Funds holding: 98 → 79 (-19)
53% less capital invested
Capital invested by funds: $138M → $64.6M (-$73.9M)
68% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$9.69M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.44M |
| 3 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$1.05M |
| 4 |
Goldman Sachs
New York
|
+$506K |
| 5 |
D.E. Shaw & Co
New York
|
+$419K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.5M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.76M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$954K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$513K |
| 5 |
FI
Fosun International
Hong Kong,
China
|
-$471K |
ABEO Hedge Fund Activity: Q3 2019 in Review
79 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q3 2019, worth a combined $64.6M — down 53% from $138M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of ABEO and 9 opened new positions — a net loss of 19 holders — while 23 trimmed existing stakes and 27 added.
The largest buyer was Great Point Partners, opening a new position worth an estimated $9.69M. The largest seller was Fidelity Investments, cutting an estimated $10.5M.
- 79 institutional investors held Abeona Therapeutics (ABEO) as of Q3 2019, down from 98 in Q2 2019.
- Funds reported $64.6M of Abeona Therapeutics stock for Q3 2019, down 53% quarter-over-quarter.
- 9 funds opened new Abeona Therapeutics positions in Q3 2019 and 28 closed out, a net change of -19 holders.
- The largest Abeona Therapeutics buyer in Q3 2019 was Great Point Partners, an estimated $9.69M added.
- The largest Abeona Therapeutics seller in Q3 2019 was Fidelity Investments, an estimated $10.5M sold.
Based on aggregated 13F filings for Q3 2019.